TY  - JOUR
AU  - Verma, Sunil
AU  - O'Shaughnessy, Joyce
AU  - Burris, Howard A
AU  - Campone, Mario
AU  - Alba, Emilio
AU  - Chandiwana, David
AU  - Dalal, Anand A
AU  - Sutradhar, Santosh
AU  - Monaco, Mauricio
AU  - Janni, Wolfgang
PY  - 2018
DO  - 10.1007/s10549-018-4769-z
UR  - http://hdl.handle.net/10668/12348
T2  - Breast cancer research and treatment
AB  - Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with first-line ribociclib plus letrozole. In the phase...
LA  - en
KW  - Advanced breast cancer
KW  - CDK4/6 inhibitor
KW  - Endocrine therapy
KW  - Health-related quality of life
KW  - Hormone receptor-positive
KW  - Ribociclib
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Letrozole
KW  - Middle Aged
KW  - Postmenopause
KW  - Purines
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Young Adult
TI  - Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
TY  - research article
VL  - 170
ER  -